Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program.

Roberts, C; Kaplow, J; Giroux, M; Krause, S; Kanekiyo, M

Roberts, C; Kaplow, J; Giroux, M; Krause, S; Kanekiyo, M.

Affiliation

Roberts C; Claire Roberts, Eisai Ltd., Hatfield, UK, Email: claire_roberts@eisai.net, Phone: +44 8456 761 590.

J Prev Alzheimers Dis ; 8(2): 218-223, 2021.

Article in En | MEDLINE | ID: mdl-33569570

Subject(s)

Amyloid/metabolism; Aniline Compounds/therapeutic use; Apolipoprotein E4/cerebrospinal fluid; Cognitive Dysfunction/drug therapy; Ethylene Glycols/therapeutic use; Amyloid/drug effects; Amyloid beta-Peptides/cerebrospinal fluid; Apolipoprotein E4/genetics; Brain/drug effects; Brain/metabolism; Cognitive Dysfunction/diagnosis; Cognitive Dysfunction/metabolism; Female; Genotype; Humans; Male; Positron-Emission Tomography/methods

Key words

APOE; Amyloid; MissionAD; elenbecestat

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ethylene Glycols / Apolipoprotein E4 / Cognitive Dysfunction / Amyloid / Aniline Compounds Type of study: Clinical_trials / Diagnostic_studies Limits: Female / Humans / Male Language: En Journal: J Prev Alzheimers Dis Year: 2021 Document type: Article Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google